Information Provided By:
Fly News Breaks for January 8, 2020
ALC, KOD, FIVN, IMVT, EVBG
Jan 8, 2020 | 10:15 EDT
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Everbridge (EVBG) initiated with a Perform at Oppenheimer. 2. Immunovant (IMVT) initiated with an Outperform at Baird. 3. Five9 (FIVN) initiated with an Outperform at Baird. 4. Kodiak Sciences (KOD) initiated with a Buy at Roth Capital. 5. Alcon (ALC) initiated with a Hold at Argus. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
News For EVBG;IMVT;FIVN;KOD;ALC From the Last 2 Days
KOD
Mar 28, 2024 | 08:59 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
KOD
Mar 28, 2024 | 06:41 EDT
"We intend to progress our portfolio of three late-stage clinical assets as rapidly as we can into Phase 3 value inflection points," said Victor Perlroth, CEO of Kodiak Sciences. "We were pleased with the Phase 1 study results of KSI-501, our anti-IL-6 and VEGF trap bispecific antibody biopolymer conjugate, in patients with diabetic macular edema ("DME"). The results of this study demonstrated that repeated monthly dosing of KSI-501 was safe and well tolerated and achieved clinically meaningful and sustained visual acuity gains. KSI-501 contains three tiers of innovation: (1) a two-target mechanism potently inhibiting both the dominant VEGF pathway and the IL-6 inflammation pathway, (2) a design based on Kodiak's ABC Platform that we believe holds the potential for 6-month durability in the majority of patients, and (3) an enhanced KSI-501 formulation informed from tarcocimab's commercial manufacturing scale-up. We believe that our supportive Phase 1 data and the multi-tiered design position the molecule to address unmet needs of patients with high prevalence retinal vascular diseases. As a result, we are planning to advance KSI-501 into a Phase 3 pivotal study (DAYBREAK) in patients with wet AMD later this year," Perlroth added.
IMVT
Mar 27, 2024 | 16:07 EDT
Oppenheimer initiated coverage of Immunovant (IMVT) with an Outperform rating and $50 price target. The firm sees Immunovant "shifting the balance of power" from Argenx (ARGX) as its anti-FcRn antibody candidates advance toward the market and looks forward to a series of late-stage trial readouts on lead asset batoclimab over the coming year, the analyst tells investors. The firm believes batoclimab's dosing flexibility and administration simplicity offer favorable differentiation from Vyvgart, the analyst added.
IMVT
Mar 26, 2024 | 07:11 EDT
JPMorgan analyst Brian Cheng reiterates Overweight ratings on Roivant Sciences (ROIV) and Immunovant (IMVT) following the recent share weakness, saying fundamentals remain solid for both companies. While Immunovant operates independently, both stories are "highly intertwined," the analyst tells investors in a research note. The firm continues to look for visibility on Roivant's plan to deploy its capital. Without clarity on the timing of the next strategic steps, sentiment around Immunovant will need time to improve, contends JPMorgan.